BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib
MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled double-blind phase three SOLO1 study of women with newly diagnosed ovarian cancer who had BRCA1/2 mutations and were treated with the poly ADP ribose polymerase (PARP) inhibitor olaparib after their standard initial platinum-based induction chemotherapy.
A three years extension of median PFS and the expectation of a robust superiority in overall survival (OS)—compared with the patients who had placebo therapy following their platinum induction chemotherapy—were reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO.
Patients will demand
“It’s practice changing. Patients are going to be demanding this when these results are made public. I think rightly so,” said first author Kathleen Moore MD, Associate Director for Clinical Research at the Stephenson Cancer Center, University of Oklahoma in Oklahoma City. “We’re going to need to get the drug approved in this line—it’s not approved in front-line [therapy] in any part of the world,” she told the Audio Journal of Oncology.